Viewing Study NCT04976634


Ignite Creation Date: 2025-12-25 @ 2:24 AM
Ignite Modification Date: 2025-12-27 @ 8:48 AM
Study NCT ID: NCT04976634
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-04-06
First Post: 2021-07-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module